T. Rowe Price Associates
OCUL icon

T. Rowe Price Associates’s Ocular Therapeutix OCUL Stock Holding History

T. Rowe Price Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50M Buy
5,897,149
+5,725,625
+3,338% +$54.6M 0.01% 770
2025
Q4 		$2.08M Buy
171,524
+39,960
+30% +$485K ﹤0.01% 1733
2025
Q3 		$1.54M Buy
131,564
+5,198
+4% +$62.2K ﹤0.01% 1854
2025
Q2 		$1.17M Buy
126,366
+625
+0.5% +$4.89K ﹤0.01% 1917
2025
Q1 		$922K Sell
125,741
-513,223
-80% -$3.94M ﹤0.01% 2003
2024
Q4 		$5.46M Sell
638,964
-338,432
-35% -$3.3M ﹤0.01% 1267
2024
Q3 		$8.5M Sell
977,396
-133,058
-12% -$1.1M ﹤0.01% 1169
2024
Q2 		$7.6M Buy
1,110,454
+447,782
+68% +$2.76M ﹤0.01% 1149
2024
Q1 		$6.03M Buy
662,672
+609,328
+1,142% +$4.32M ﹤0.01% 1184
2023
Q4 		$238K Buy
53,344
+12,859
+32% +$38K ﹤0.01% 2474
2023
Q3 		$128K Buy
40,485
+1,846
+5% +$7.55K ﹤0.01% 2616
2023
Q2 		$200K Buy
38,639
+344
+0.9% +$2.05K ﹤0.01% 2534
2023
Q1 		$202K Sell
38,295
-3,566
-9% -$16.9K ﹤0.01% 2525
2022
Q4 		$118K Buy
41,861
+10,972
+36% +$36.3K ﹤0.01% 2682
2022
Q3 		$129K Buy
30,889
+4,981
+19% +$25.1K ﹤0.01% 2663
2022
Q2 		$104K Buy
25,908
+6,167
+31% +$23.3K ﹤0.01% 2750
2022
Q1 		$98K Buy
19,741
+6,481
+49% +$35.9K ﹤0.01% 2850
2021
Q4 		$92K Sell
13,260
-21,300
-62% -$165K ﹤0.01% 2887
2021
Q3 		$346K Sell
34,560
-100
-0.3% -$1.12K ﹤0.01% 2527
2021
Q2 		$491K Buy
34,660
+1,759
+5% +$26.7K ﹤0.01% 2400
2021
Q1 		$540K Buy
32,901
+6,973
+27% +$134K ﹤0.01% 2332
2020
Q4 		$537K Buy
+25,928
New +$385K ﹤0.01% 2212

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's OCUL Position: Q1 2026 in Review

T. Rowe Price Associates increased its Ocular Therapeutix (OCUL) stake by 3,338% in Q1 2026, buying an estimated $54.6M and bringing the position to 5,897,149 shares worth $50M. The position accounts for 0.01% of the portfolio, ranked #770.

T. Rowe Price Associates first reported a position in OCUL in Q4 2020 and has held it in 22 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • T. Rowe Price Associates held 5,897,149 shares of Ocular Therapeutix worth $50M as of Q1 2026.
  • T. Rowe Price Associates bought 5,725,625 Ocular Therapeutix shares in Q1 2026, an estimated $54.6M.
  • Ocular Therapeutix made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #770 holding.
  • T. Rowe Price Associates first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 22 quarters since.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.